CN103565801A - Composition for treating fundus macular oedema and application of composition to treating eye diseases - Google Patents
Composition for treating fundus macular oedema and application of composition to treating eye diseases Download PDFInfo
- Publication number
- CN103565801A CN103565801A CN201210274126.9A CN201210274126A CN103565801A CN 103565801 A CN103565801 A CN 103565801A CN 201210274126 A CN201210274126 A CN 201210274126A CN 103565801 A CN103565801 A CN 103565801A
- Authority
- CN
- China
- Prior art keywords
- acid
- optical fundus
- macular edema
- treatment
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition for treating fundus macular oedema and application of the composition in treatment of eye diseases and belongs to the technical field of medicines. The composition for treating the fundus macular oedema comprises the following components in percentage by weight: 0.4-71% of (a) polyphenolic compounds, 0.6-93% of (b) lipoic acid, dihydrolipoic acid, lipoic acid salt or lipoamide, 0-97% of (c) ubiquinone or panthenol and 0-87% of (d) docosahexaenoic acid or ethyl ester thereof and/or timnodonic acid or ethyl ester thereof. The composition can be used for improving patient visual acuity, stabilizing intraocular pressure and reducing various ocular inflammations such as the fundus macular oedema. By means of the composition for treating the fundus macular oedema and a treatment method, the fundus macular oedema can be prevented, stabilized, controlled or treated and the fundus health can be enhanced; in the meantime, the intraocular pressure can be stabilized, the vision can be maintained or improved, various eye diseases or macular oedema and inflammation which are caused by eye operations can be reduced; the diabetic complication is also treated, the blood microcirculation is promoted and the liver function is improved.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of compositions and the application of said composition in treatment ocular disease that is used for the treatment of ocular disease.
Background technology
In Chinese adult especially old people, cause at present that blind and principal disease visual disorder has cataract, old optical fundus maculopathy, Myopia optical fundus maculopathy, also has glaucoma.Diabetes patient's complication is embodied in eye in quite a few people, causes blurred vision, even blind.In European and American areas, cause that blind principal disease has old optical fundus maculopathy, glaucoma, cataract, and diabetic retinopathy.Arthritis, heart disease and visual deterioration are to the three large diseases that directly cause daily life and moving obstacle in the people over 70.According to prediction, to the year two thousand twenty, the blind or amblyopia by the American who has nearly 6,000,000.
The deposit of liquid or protein is in the upper and lower accumulation of optical fundus macula lutea, and optical fundus macular edema will occur, and makes optical fundus macula lutea thickening swelling.It has changed retinal cell function of eyes, inspires inflammation and causes visual loss.Optical fundus macular edema may occur in retina cell or extracellular.The accumulation of extracellular liquid more often occurs, and clinical discovery is more.The change that it and blood vessel-retina shield has direct relation.
One of the reason that causes the disease of optical fundus macular edema is that retinal vein stops up, and comprises that retina cardinal vein or branch's vein stop up.The feature that retinal vein stops up is retinal vein expansion enlargement, the inter-retinal hemorrhage of secondary, and because of blood vessel blockage, blood supply insufficiency and cause retinal ischemia.
Having several method to be used for controlling retina cardinal vein stops up.Wherein the effect of grid-like Photocoagulation is poor.Intravitreal injection hormone may cause a series of serious adverse side effects such as cataract, high intraocular pressure.The current side effect of intravitreal injection of VEGF antibody is relatively smaller.The control of optical fundus macular edema is had to certain prospect.There is about macular edema patient of 30 percent to the intravitreal injection reaction of VEGF antibody not obvious.In addition, intravitreal injection belongs to " having wound " method, needs professional external coat doctor's operation, somewhat expensive.The more important thing is that its Main Function is to control the state of an illness but can not cure, patient needs regularly repeatedly to accept intravitreal injection.This regular injection for curing usually need to adhere to maintaining throughout one's life the state of an illness, to patient, brings a lot of inconvenience.
The macula area edema that diabetes cause thickens the macula area at retina middle part, is in diabetics, to cause blind most commonly encountered diseases disease.Diabetic macula area edema patient has accounted for about 1 14 in diabetics.The lasting time length of the generation of diabetic macula area edema and the degree weight of diabetic renal papillary necrosis and pathological changes is closely connected.Diabetic renal papillary necrosis, because of destroyed the causing of interior blood vessel-retina shielding, causes material in blood plasma to leak into around retina.Macula area edema or blood capillary ischemia be harm central vision directly.
Suffer from the crowd of type-II diabetes about 5 years, have 10 to occur macula area edema.Suffer from type-II diabetes and reach in vicennial patient, occur that the probability of macula area edema can be increased to more than 30 percent.Suffer from the crowd of type diabetes about 5 years and occur that the probability of macula area edema is relatively low, but reach in vicennial patient suffering from type diabetes, the probability of macula area edema also can be increased to more than 30 percent.In patient, the probability of the appearance macula area edema of use insulin is higher.Photocoagulation is the standard treatments of controlling the macula area edema that diabetes cause.But photocoagulation is not good enough to a lot of patient's curative effects.Current Therapeutic Method also has intravitreal injection hormone.But well-known, such therapy has side effect, for example, may cause that it is one of them that intraocular pressure increases.
The macula area edema patient's who causes in diabetes intravitreous endothelial cell growth factor (ECGF) content is relatively high.Therefore with intravitreous endothelial cell growth factor (ECGF) antibody, treat the method that becomes the macula area edema that general treatment diabetes cause.But the intravitreal injection of long term repeatability can increase infectious endophthalmitis occurrence probability, become a large disadvantage of intravitreal injection.
In industrialized country, cause that central area vision main disease blind or low vision is exactly old optical fundus maculopathy, be also degeneration.In the U.S., nearly 10,000,000 populations suffer from old optical fundus maculopathy, and wherein nearly two million peoples suffer from later stage old optical fundus maculopathy, are also called moist old optical fundus maculopathy.Another is the old optical fundus of dryness maculopathy, belongs to the maculopathy of commitment.The old optical fundus of dryness maculopathy is mainly because of people's old and feeble macula lutea, to organize attenuation and pigment spot to be deposited on these two factors of macula area to cause.
Except above-described several diseases, other diseases is as glaucoma etc., some operated eye, and medicine, also may cause macular edema.For diabetes or hypertensive patient, first feasible method is its diabetes of systemic treatment and hypertension, to reduce this disease for the further destruction on optical fundus.Oral drugs for example.But after systemic treatment, the medicine of oral medication retinal diseases, it is lower that its active component can enter amphiblestroid bioavailability.Active component need to reach a certain amount of competence exertion therapeutic effect at retina in addition, and oral dosage need to increase for this reason, if medicine has side effect to work as consumption when large, just may cause the harmful effect to whole body.
Summary of the invention
The present invention is in order to overcome the defect existing in background technology, and a kind of compositions and the application of said composition in treatment ocular disease that is used for the treatment of optical fundus macular edema is provided.The present invention has developed a new direction, use to whole body there is composition that nutrition health-care functions is free from side effects again, with best proportioning, reach treatment optical fundus macular edema object.
This compositions that is used for the treatment of optical fundus macular edema comprises by weight percentage: (a) polyphenol compound of 0.4% ~ 71%, 0.6% ~ 93% (b) thioctic acid, dihydrolipoic acid, lipoate or lipoic acid polyacrylamide, 0% ~ 97% (c) ubiquinone or pantothenylol, 0% ~ 87% (d) docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
The described compositions that is used for the treatment of optical fundus macular edema comprises by weight percentage: (a) polyphenol compound of 0.4% ~ 71%, 0.6% ~ 93% (b) thioctic acid, dihydrolipoic acid, lipoate or lipoic acid polyacrylamide, 0.6% ~ 97% (c) ubiquinone or pantothenylol, 0.15% ~ 87% (d) docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
The described compositions that is used for the treatment of optical fundus macular edema comprises: (a) polyphenol compound of 25 ~ 800 milligrams, (b) thioctic acid, dihydrolipoic acid, lipoate or the lipoic acid polyacrylamide of 25 ~ 1800 milligrams, (c) ubiquinone or the pantothenylol of 0 ~ 1000 milligram, d) docosahexenoic acid of 0 ~ 2000 milligram or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
The described compositions that is used for the treatment of optical fundus macular edema also comprises the vitamin A of 0 ~ 1000 IU, the vitamin B of 0 ~ 1000 milligram, vitamin C, the vitamin D of 0 ~ 5000 IU and the vitamin E of 0 ~ 800 IU of 0 ~ 2000 milligram, the zinc of 0 ~ 40 milligram, the magnesium of 0 ~ 900 milligram, the carotenoid material of 0 ~ 500 milligram.
The compositions that is used for the treatment of optical fundus macular edema of stating is for improving patient's vision stability intraocular pressure and reducing all kinds of inflammation of eye.
The described compositions that is used for the treatment of optical fundus macular edema is used for the treatment of optical fundus macular edema.
The described compositions that is used for the treatment of optical fundus macular edema is used for the treatment of patient to be had due to diabetes, hypertension, angiopathy comprises arteriosclerosis, all kinds of ophthalmics, cancer, optical fundus blood vessel disease, some rare disease, the optical fundus macular edema that smoking or ocular surgical cause and other ocular disease, described optical fundus blood vessel disease comprises that central retina vein stops up, branch retinal vein stops up, old optical fundus macula lutea degeneration, the combination of glaucoma or several diseases.
It is oral, eye drip, intravitreal injection, intravenous drip, external preparation for skin that the described compositions that is used for the treatment of optical fundus macular edema is taken in approach in body, without intestinal, intraperitoneal, Sublingual or implant.
The daily dose that the described compositions that is used for the treatment of optical fundus macular edema is taken in body is: the former Hua Qingsu of 30 ~ 300mg, 30 ~ 600mg thioctic acid, 50 ~ 300mg ubiquinone, 100 ~ 1500 milligrams of docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
The described compositions that is used for the treatment of optical fundus macular edema further adds the anti-inflammation formulation of medical effective dose to patient, antibiotic medicine is oral formulations, eye drop, unguentum or transdermal patch, or further to patient, add by endothelial cell growth factor (ECGF) antibody class compositions, or further comprise laser coagulation therapeutic scheme.
The present invention has following beneficial effect:
Compositions and Therapeutic Method that the present invention is used for the treatment of optical fundus macular edema can prevent, stablize, control or treat optical fundus macular edema, strengthen optical fundus health.Simultaneously can also stablize intraocular pressure, keep or improve vision, the macular edema and the inflammation that alleviate various ocular disease or cause because of operated eye.Also treat diabetic complication, promote blood microcirculation, improve liver function.
Accompanying drawing explanation
Fig. 1 is that left eye suffers from optical fundus optical coherence tomography (OCT) photo of optical fundus macular edema patient when not taking the compositions of this invention.
Fig. 2 is optical fundus optical coherence tomography (OCT) photo after compositions of the present invention for same clothes for patients.
The specific embodiment
Present embodiment provides a kind of compositions for the treatment of optical fundus macular edema, wherein need to contain (a) polyphenol compound, (b) thioctic acid, dihydrolipoic acid, or its salt or amide compound, (c) ubiquinone or pantothenylol, (d) docosahexenoic acid or its ethyl ester compound and/or eicosapentaenoic acid or its ethyl ester compound.
Polyphenol substance is one or more procyanidin polymers.Combination mixture can comprise following vitamin: A, B, C, D, the mixture of a kind of or its several vitamin in E simultaneously.This component can further contain mineral, zinc for example, and the oxide of magnesium, or its esters, can be one of them, also can the two combination.In some cases, this component contains pharmaceutically acceptable carrier mass.
In an object lesson, this invention component is 25-800 milligram anthocyanidin polymer, 25-1800 milligram thioctic acid, 0-2000 milligram docosahexenoic acid or its ethyl ester compound and/or eicosapentaenoic acid or its ethyl ester compound, 0-1000 milligram ubiquinone; In another object lesson, the former Hua Qingsu polymer of 30-300 milligram, 30-600 milligram thioctic acid, 100-1500 milligram docosahexenoic acid or its ethyl ester compound and/or eicosapentaenoic acid or its ethyl ester compound, and 50-300 milligram ubiquinone.
This component can be made tablet, capsule or liquid oral.
Another examples of implementation of this invention, only contain following component (a) polyphenolic substance of effective dose, (b) thioctic acid, or lipoate, or lipoic acid polyacrylamide, (c) ubiquinone or pantothenylol; (d) docosahexenoic acid or its ethyl lipoid substance and/or eicosapentaenoic acid or its ethyl ester compounds; This composition further can also contain from following vitamin and mineral and select one or more: vitamin A, B, C, D, E, the oxide of zinc or salt, and/or the oxide of magnesium or salt.This composition further can also contain carotenoid material, as terpenoid.
The present invention also provides the method for processing and control macular edema.The method that optical fundus macular edema prevents its deterioration that maintains is provided in one embodiment.
In another case study on implementation, provide the method that optical fundus macular edema patient is effectively treated.The cause of optical fundus macular edema is numerous, comprising: diabetes, optical fundus blood vessel disease, some drugs, some non-common disease or indivedual ocular surgical cause.Wherein optical fundus blood vessel disease has comprised that optical fundus central retina vein stops up, and branch retinal vein stops up, old macula lutea degeneration, glaucoma, or the syndrome of several sick combinations.
The method that this component is introduced human body comprises: oral, necessary words also can intravitreal injection, external preparation for skin, and intravenous injection, parenteral absorption, intraperitoneal is introduced, and introduce in Sublingual or oral cavity, for not restriction of administering mode.
A Therapeutic Method example, the dosage of every day: 30-300 milligram Hua Qingsu polymer, 30-600 milligram thioctic acid, 100-1500 milligram docosahexenoic acid or its ethyl ester compound and/or eicosapentaenoic acid or its ethyl ester compound, and 50-300 milligram ubiquinone.
In some cases, the method for processing, controlling or treat, also comprises except taking this component and allows patient absorb anti-inflammation drugs simultaneously, this anti-inflammation drugs can be non-hormone antibiotic medicine.In other situations, it can be also the anti-inflammation drugs containing hormone.In some cases, use precursor anti-inflammation drugs.Antibiotic medicine can be oral, as collyrium external, can be paste, sees through transdermal patch, or through cornea, sclera/conjunctiva by way of.
In examples of implementation, Therapeutic Method can also comprise when taking this component introduces VEGF antibody, or further comprise introduce carbonic anhydrase inhibitors or its in early stage medicine.In examples of implementation, the medicine of simultaneously introducing can also comprise immunosuppressant, or its medicine in early stage.In examples of implementation, Therapeutic Method also comprises operated eye, for example laser light freezing method or photodynamic therapy.
The invention provides digital proof the component stated can effectively treat optical fundus macular edema and eliminate relevant symptom.
" effective dose " is one and takes in or the quantity of administration can be enough to reach patient and is benefited or desirable effect.Effective dose can be that one or many is taken in, and takes or the dosage of application.Conduction in human body, or discharge and to depend on a lot of parameters, comprise the interval that each dosage unit is used, the bioavailability of therapeutant agent, introducing method.The effective dose level that is appreciated that healing potion of the present invention depends on many factors, the activity of the component of for example using, the bioavailability of component, introducing method, patient age and body weight, health status, sex, patient's diet, Time of Administration, excretion degree, the medicine of while use, the medicine of meanwhile taking because of other diseases, patient's coincident with severity degree of condition, treatment and absorption mode.Therapeutic dose can carry out by optimizing safety and curative effect the calculating of titration formula.Very common way: thus from the relation that dosage and curative effect are found out in test tube test and human trial, to the suitable dosage of patient, provide the guidance of use.Animal test model generally can be used for the effective dose of guiding treatment disease.These consider, and effectively fill a prescription and absorption process not rarely known by the people technically, and have description on the textbook of standard.To determine meaning consistent with this, and treating effective dose is here that a dosage is enough to treat special disease, or in other words obtains the response on pharmacology.
The meaning of the noun here " absorption " or " administration " or " introducing " is including, but not limited to following manner: dosing eyes, oral, without intestinal, take in (intramuscular injection, peritoneum introducing, suck, see through skin and introduce, intravenous drip, ocular injection) nose spraying suction, vagina, anus, Sublingual, urethra or external preparation for skin.External application can be jelly, ointment, and cream, spraying, the forms such as medicament for the eyes, can make various formulas, may contain traditional harmless nontoxic medical science acceptable carrier or excipient, and these depend on medicine introducing mode.This invention is not limited to above-mentioned absorption mode, the interval of formula or administration.
The meaning of " processing " here or " treatment " disease is: 1) for there being this disease tendency still also not produce in the situation of symptom, and prophylactic generation; 2) suppress disease restriction disease progression; 3) improve or disease or its symptom are dwindled; Processing or treating is in order to obtain the benefit of medicine or desirable effect, to comprise clinical trial result.Object of the present invention, benefit or desired result can include, but are not limited to: alleviate, relax or improve one or more symptoms, reduce the interval time between other dosage or growth treatment and treatment and reach better curative effect or maintain the state of an illness, reduce the order of severity of disease, stablize current disease condition, slow down delay advancing of disease, improvement alleviates the state of an illness and is partly or entirely eased, and no matter is the alleviation that can detect or can't detect.From saying on the one hand, the treatment of macular edema comprises reduction or maintains the macula lutea layer thickness (can measure by optical fundus optical coherence tomography (OCT)) after the macular edema of optical fundus, improves or maintain vision making it no longer to worsen.On the other hand, the treatment of macular edema comprises repairs optical fundus retinal blood tube wall, improves ocular angiogenesis microcirculation.The treatment of optical fundus macular edema also comprises and slows down optical fundus macula lutea degeneration.Also may improve glaucomatous intraocular pressure in addition, alleviate the oxidation of optic cell and tissue.
Optical fundus macular edema is because hydrops in each layer of retina around optical fundus retinal centre nest causes.Owing to having changed optical fundus functioning cell relatedness and having encouraged inflammation reparation reaction, thereby reduce or DE.This be optical fundus macula lutea for optical fundus environmental change have clinical correlation type reaction, in most of the cases, the change of macular edema and blood vessel-retinal barrier has relation.Optical fundus macular edema is more than lasting half a year, can think macular edema at the bottom of chronic eye, needs treatment.
The present invention includes four special combination that are proved to be clinically as the component of safety: 1) polyphenolic substance
,former Hua Qingsu for example, 2) thioctic acid 3) ubiquinone, 4) Omega-3 fatty acid, comprise docosahexenoic acid or its ethyl ester compound and/or eicosapentaenoic acid or its ethyl ester compound.These materials can effectively be treated optical fundus macular edema with the combination of best proportioning.It is contemplated that, each component has its advantage.When putting together, they reduce the penetrance of blood vessel wall, and protection retinal epithelium and endotheliocyte increase microcirculation, reduce the side effect that VEGF rose.Furthermore, the formula of oral this invention, may have certain help to diabetes and hypertensive patient.
Thioctic acid
,and its reduction-state, dihydrolipoic acid, can reduce the too high permeability of blood vessel, reduces the formation of free radical and the formation of cytochrome C of oxygen.As potent antioxidant, it can prevent the oxidation of epidermis and the endotheliocyte of blood vessel wall.Thioctic acid has water solublity and has again oil-soluble, and it can pass the shielding of blood-retina and enter optical fundus portion.By oral way, when taking when a certain amount of, it can reach the level for the treatment of in the bioavailability on optical fundus.
Polyphenolic substance, catechol for example, epicatechin, multiclass Hua Qingsu can increase microcirculation, lowers the microangiopathies that microangiopathies, particularly diabetes cause.
Europe rice Jia (Omega) fatty acid is Europe rice Jia-3 fatty acid especially, from another point of view, thereby has the character protection optical fundus of anti-angiogenic regeneration, and its reduces the revascularization producing because of vascular endothelial cell growth factor, keeps the sound of blood vessel.The synergism that is combined with the endothelial cell growth resisting factor of Omega-3 fatty acid and thioctic acid.
Ubiquinone exists on optical fundus conventionally, and its content reduces with age growth.People have known ought be Omega-3 fatty acid, with acetyl-L-carnitine and ubiquinone in conjunction with can be by improving mitochondria dysfunction, treat relevant optical fundus macula lutea degeneration of early stage age, the present invention is ubiquinone, omega-3 fatty acid, thioctic acid and the combination of multiclass anthocyanidin, do not need L-acetylcarnitine can play even better effect of same purpose.
Therefore one embodiment of the present of invention provide a composition, contain following composition, and each component reaches effective dose, and (a) polyphenol compound particularly extracts from plant.(b) thioctic acid, dihydrolipoic acid, and/or its salt or its amide; (c) ubiquinone or pantothenylol; (d) docosahexenoic acid or its ethyl ester compound and/or eicosapentaenoic acid or its ethyl ester compound.
Polyphenolic substance, for example procyanidin is antioxidant.
" polyphenolic substance " refers to and on a construction unit, has two phenol structures at least in one embodiment, and polyphenolic substance is not rarely known by the people technically.Can synthesize, or by purifying, obtain from natural environment.Polyphenolic substance in the present invention is from natural source.Polyphenolic substance includes but not limited to Hydrolysable Tannins acid, (glucose, or the gallic acid ester of other sugar or cyclic alcohol) and phenolic group propionic ester, for example lignin, flavone compound, condensed tannin and phenolic acid.
Chromocor compound is including, but not limited to flavonol, (or flavane-3 alcohol), flavone, anthocyanidin, isomery flavone, and neoflavone.In an object lesson, flavanol compound is procyanidin, or procyanidin apoplexy due to endogenous wind is a kind of.
Procyanidin class, also referred to as the former Hua Qingsu of oligomer, or OPCs, refer to former Hua Qingsu, former Hua Qingsu analog, poly-lignin etc., especially for example, for example,, as flavane-3 alcohol (catechol, epicatechol and/or its polymer) and flavone (Taxifolin), epicatechol structure is as follows:
Catechol structure is as follows:
Alpha-lipoic acid, it is sad to vulcanize, or LIPOIC ACID, is also called (R)-5-(1,2-disulphanes-3) valeric acid structure is as follows
: 
.
Dihydrolipoic acid is 6,8
-the sad structure of dimercapto is as follows:
The amide of thioctic acid can be but be not limited to di alkylamino group ethylamino-lipoate.
Ubiquinone structure is as follows:
Pantothenylol is the reduction form of ubiquinone.
twododecahexaene acid and eicosapentaenoic acid are all Europe rice Jia fatty acids, unsaturated fatty acid namely, and position of double bond is from the 3rd carbon atom of carbochain end..
The structure of docosahexenoic acid (DHA):
?the structure of eicosapentaenoic acid (PHA) is as follows:
In one embodiment, this component further contains vitamin, can from following vitamin, choose.Vitamin A, B, C, D, E or its combination.
In another embodiment, this component further contains mineral, zinc for example, and magnesium etc., can be the form of oxide or salt.
Another one embodiment, this invention component of one side only contains basis and is: a) polyphenol compound, b) thioctic acid or dihydrolipoic acid, or its salt or amide, c) ubiquinone or pantothenylol, d) docosahexenoic acid or its ethyl ester and/or eicosapentaenoic acid or its ethyl ester.
This component can also contain vitamin on the other hand, mineral or its combination.
This component can also contain carotenoid material on the other hand, as terpenoid, particularly can penetrate the terpenoid of blood vessel-retina shielding.
In this patent, the meaning of " basic composition " or " only containing " is to get rid of those to change the composition of the character of this invention component.On the one hand, the fundamental property of this invention component comprises biological effectiveness and avirulence.On the other hand, the fundamental property " only containing " also comprises that this component of at least a portion can see through blood-retina barrier.This component does not contain the extract of some a large amount of plants, Pericarpium Citri tangerinae for example, Bulbus Allii, curcumin, Ye Xiang, black pepper, Cortex cocois radicis.On the one hand, this component does not contain the part of the following full fruit of a great deal of, Fructus Lycopersici esculenti for example, Brassica oleracea L. var. botrytis L., Chinese cabbage, Herba Spinaciae, and Radix Dauci Sativae.The component of this invention does not contain a large amount of Monas cuspurpureus Wents, spermine acid, L-Tyrosine, biotin, choline, inositol, methyl yellow acyl methane, para-amino benzoic acid.Hyaluronic acid, iodine or its salt.Here the meaning that is less than a large amount of components of indication is 50%, 40%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% of component, 0.5%, 0.1% or 0.01% (weight by weight).
In one embodiment, this component further contains acceptable carrier on materia medica." acceptable carrier on materia medica " contained any or all solvents, disperse medium, and coating, antibiotic and antifungal agents, isotonic agent, absorbs the analog such as delayer.It is well-known for pharmaceutically active substance, using this class medium.Except reagent or the medium that does not mate or avoid with active component, their uses in treatment component are ripe, and active helper component also can add this component.
In a specific embodiments, this component contains about 20-800 milligram polyphenolic substance, procyanidin for example,
25-1800 milligram thioctic acid, dihydrolipoic acid or its salt or its amide,
20-1000 milligram ubiquinone or pantothenylol,
100-2000 milligram docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
A kind of situation polyphenolic substance a) namely the quantity of procyanidin be 25-200 milligram, 25-300 milligram, 25-400 milligram, 30-800 milligram, 30-600 milligram, 30-400 milligram, 40-300 milligram, 40-400 milligram, 40-800 milligram, 50-200 milligram, 50-300 milligram, 50-400 milligram, 50-800 milligram, 60-200 milligram, 60-300 milligram, 60-400 milligram, 60-800 milligram, 65-400 milligram, 65-800 milligram, 70-400 milligram, 70-600 milligram, 70-800 milligram, 80-500 milligram, 80-800 milligram, 100-800 milligram, or 100-600 milligram.
A kind of situation, b) thioctic acid or dihydrolipoic acid or its salt, or the quantity of its amide is 25-1800 milligram, 25-1500 milligram, 25-1000 milligram, 25-800 milligram, 30-1800 milligram, 30-1600 milligram, 30-1200 milligram, 30-1000 milligram, 30-800 milligram, 50 800 milligrams of –, 50 1000 milligrams of –, 100 1000 milligrams of –, 100 1800 milligrams of –, 150 900 milligrams of –, 150 1500 milligrams of –, 150 1800 milligrams of –, 200 600 milligrams of –, 200 800 milligrams of –, 200 1000 milligrams of –, 200 1800 milligrams of –, 250 1800 milligrams of –, 250 900 milligrams of –, 250 1500 milligrams of –, 300 800 milligrams of –, 300 1800 milligrams of –, 300 1500 milligrams of –, 350 1000 milligrams of –, 400 1800 milligrams of –, 450 1800 milligrams of –, 500 1800 milligrams of –, 1800 milligrams of 550 1800 milligrams of – or 600 –.
On the one hand, c) quantity of ubiquinone or pantothenylol is 1000 milligrams of 0 –, 0 300 milligrams of –, 0 600 milligrams of –, 35 800 milligrams of –, 35 1000 milligrams of –, 40 600 milligrams of –, 40 1000 milligrams of –, 50 500 milligrams of –, 50 800 milligrams of –, 50 1000 milligrams of –, 60 1000 milligrams of –, 60 800 milligrams of –, 80 800 milligrams of –, 80 400 milligrams of –, 80 500 milligrams of –, 80 600 milligrams of –, 100 300 milligrams of –, 100 600 milligrams of –, 100 800 milligrams of –, 150-1000 milligram, 150 800 milligrams of –, 200 1000 milligrams of –, 220 800 milligrams of –, or 1000 milligrams of 250 –.
D on the other hand) docosahexenoic acid or its ethyl ester and/or eicosapentaenoic acid or its ethyl ester or the quantity that merges are together 2000 milligrams of 0 –, 0 1000 milligrams of –, 100 600 milligrams of –, 100 1800 milligrams of –, 120 1000 milligrams of –, 120 2000 milligrams of –, 150 800 milligrams of –, 150 2000 milligrams of –, 200 2000 milligrams of –, 250 2000 milligrams of –, 400 2000 milligrams of –, 400 1500 milligrams of –, 500 1500 milligrams of –, 500 2000 milligrams of –, 600 1800 milligrams of –, 700 1800 milligrams of –, 800 1500 milligrams of –, 2000 milligrams of 800 2000 milligrams of – or 1000 –.
In another embodiment, this invention component contains: 30 300 milligrams of – (a) polyphenolic substances, 30 600 milligrams of – (b) thioctic acid, or dihydrolipoic acid, its salt or its amide, 50 300 milligrams of – (c) ubiquinone or pantothenylol, 100 1500 milligrams of – (d) docosahexenoic acid or its ethyl esters, and eicosapentaenoic acid or its ethyl ester.
In another embodiment, this invention component contains:
?the former Hua Qingsu oligomer of 25 800 milligrams of –, 25 1800 milligrams of – thioctic acid, 100 2000 milligrams of – docosahexenoic acid and eicosapentaenoic acid, 20 1000 milligrams of – ubiquinone.
In above-described any one embodiment, component further comprise following wherein at least one: the upper limit reaches 1000 IU vitamin A, the upper limit reaches 1000 milligrams of vitamin Bs, the upper limit reaches 2000 milligrams of vitamin Cs, the upper limit reaches 5000IU vitamin D, and the upper limit reaches 800IU vitamin E, and the upper limit reaches 40 milligrams of equivalent that are equivalent to zinc, the upper limit reaches 900 milligrams of equivalent that are equivalent to magnesium, and the upper limit reaches about 500 milligrams of terpenoids.
In one embodiment, this invention component contains: the former Hua Qingsu of 0.4%-71% (weight by weight), 0.6%-93% (weight by weight) thioctic acid, 0.6%-97% (weight by weight) docosahexenoic acid and eicosapentaenoic acid, 0.15%-87% (weight by weight) ubiquinone.
In one embodiment, this invention component contains: the former Hua Qingsu of 2%-55% (weight by weight), 2%-70% (weight by weight) thioctic acid, 10%-60% (weight by weight) docosahexenoic acid and merging eicosapentaenoic acid, 2%-45% (weight by weight) ubiquinone.
In one embodiment, this invention component contains: the former Hua Qingsu of 2%-55% (weight by weight), 2%-70% (weight by weight) thioctic acid, 15%-50% (weight by weight) docosahexenoic acid and merging eicosapentaenoic acid, 0.5%-40% (weight by weight) ubiquinone.
In one embodiment, this invention component contains the former Hua Qingsu of 3%-60% (weight by weight), 3%-70% (weight by weight) thioctic acid, 1%-50% (weight by weight) docosahexenoic acid and merging eicosapentaenoic acid, 0.2%-40%(weight by weight) ubiquinone.
In one embodiment, this invention component contains: the former Hua Qingsu of 4%-60% (weight by weight), 4%-70% (weight by weight) thioctic acid, 1%-50% (weight by weight) docosahexenoic acid and merging eicosapentaenoic acid, 0.2%-30% (weight by weight) ubiquinone.
In one embodiment, this invention component contains: the former Hua Qingsu of 5%-65% (weight by weight), 5%-70% (weight by weight) thioctic acid, 1%-50% (weight by weight) docosahexenoic acid and merging eicosapentaenoic acid, approximately 0.2%-25% (weight by weight) ubiquinone.
In one embodiment, this invention component contains: the former Hua Qingsu of 10%-65% (weight by weight), 10%-70% (weight by weight) thioctic acid, 5%-45% (weight by weight) docosahexenoic acid and eicosapentaenoic acid, 0.2%-25% (weight by weight) ubiquinone.
In another embodiment, this component contains: the former Hua Qingsu of 15%-60% (weight by weight), 15%-70% (weight by weight) thioctic acid, 5%-45% (weight by weight) docosahexenoic acid and eicosapentaenoic acid, 0.2%-25% (weight by weight) ubiquinone.
In another embodiment, this component contains: the former Hua Qingsu of 20%-65% (weight by weight), 10%-70% (weight by weight) thioctic acid, 0%-30% (weight by weight) docosahexenoic acid and eicosapentaenoic acid, 0%-25% (weight by weight) ubiquinone.
In another embodiment, this component contains: the former Hua Qingsu of 10%-60% (weight by weight), 20%-60% (weight by weight) thioctic acid, 5%-30% (weight by weight) docosahexenoic acid and eicosapentaenoic acid, 0.2%-20% (weight by weight) ubiquinone.
In another embodiment, this component contains: the former Hua Qingsu of 25%-60% (weight by weight), 10%-60% (weight by weight) thioctic acid, 10%-30% (weight by weight) docosahexenoic acid and eicosapentaenoic acid, 0.2%-20% (weight by weight) ubiquinone.
In certain embodiments, former Hua Qingsu, thioctic acid, docosahexenoic acid and eicosapentaenoic acid and ubiquinone combine account for whole component quantity be at least 10%(weight by weight), or be at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80% or 90%(weight by weight).
The recipe ingredient scope that table 1 is taken every day for example
| Composition | Exemplify compositing range: |
| Omega-3 |
0 1500 milligrams of – |
| Thioctic acid | 30 600 milligrams of – |
| |
0 300 milligrams of – |
| Former Hua Qingsu | 30 300 milligrams of – |
| |
0 – 1500 IU |
| |
0 800 milligrams of – |
| |
0 500 milligrams of – |
| Vitamin A | 0 – 1000 |
| Vitamin E | |
| 0 – 400 | |
| Zinc oxide | |
| 0 35 milligrams of – | |
| |
0 450 milligrams of – |
| Terpenoid | 0-500 milligram |
The using method of this invention different component collocation is here provided.These components can be prevented, stablize and maintain and/or treat optical fundus macular edema, and can effectively improve vision, maintain intraocular pressure, to stopping up by central retina vein the glaucoma causing, there is certain curative effect, slow down optical fundus macula lutea degeneration and/or reduce inflammation, can also treat or improve some other disease, orphan disease or operated eye and the macular edema that causes.
Therefore, in one embodiment, offer Therapeutic Method of optical fundus macular edema patient, allow exactly clothes for patients use can reach the effective dose of this invention said components of therapeutic effect.The effective dose by taking this component with treatment effect is provided in addition in one embodiment, can have improved the method for optical fundus macular edema patient vision.
Supplying method is by taking this invention component effective dose, to reduce optical fundus macula lutea patient's inflammation in another embodiment.
, optical fundus macula lutea patient may be due to but is not limited to diabetes or optical fundus blood vessel disease.The initiation of optical fundus blood vessel disease may be because optical fundus central vein of the retina stops up, and optical fundus branch retinal vein stops up, also may be due to old optical fundus macula lutea degeneration, and glaucoma or several disease cause altogether.Also may be not common disease and indirectly causing of operated eye or other.
, total daily dose is as follows: the former Hua Qingsu of 30 300 milligrams of –, 30 600 milligrams of – thioctic acid, 100 1500 milligrams of – docosahexenoic acid and eicosapentaenoic acid, 50 300 milligrams of – ubiquinone.
In one embodiment, day is taken in composition and intake is: the former Hua Qingsu of 30 300 milligrams of –, 30 600 milligrams of – thioctic acid, 100 1500 milligrams of – docosahexenoic acid and eicosapentaenoic acid, 50 300 milligrams of – ubiquinone, one of following ingredients at least: the upper limit is up to 1000IU vitamin A, the upper limit is up to 800 milligrams of vitamin Bs, the upper limit is up to 1000 milligrams of vitamin Cs, the upper limit is up to 2000IU vitamin D, the upper limit is up to 400IU vitamin E, the upper limit is up to 35 milligrams of amounts that are equivalent to zinc, the upper limit is up to 450 milligrams of amounts that are equivalent to magnesium, the upper limit reaches 500 milligrams of terpenoids.
In some cases, patient can further take in the treatment anti-inflammation formulation of effective dose or its in early stage medicine, it can be eye drop, the unguentum that skin is used can transdermal patch or grafting treatment.Patient can also take in the antibody of anti-endothelial cell growth factor (ECGF), can adopt non-intestinal to take in way.In another situation, patient can accept ocular surgical, for example radium-shine photic coacervation.
In above-mentioned all embodiment any one, the preparation of this invention component can be tablet, capsule, or be liquid, or be eye drop, or be emulsifiable paste, or be can transdermal patch, or implantation preparation.
In component administering mode of the present invention or absorption body, method can be oral, eye vitreous injection, and external, Sublingual, buccal, nasal cavity, feeds without intestinal, intramuscular injection, peritoneum, vein or subcutaneous injection, mouthspray or nose spraying.This component can according to dosage be filled a prescription according to the mode of taking in body.
Can be with the method preparation of conventionally knowing for the tablet of component of the present invention (may contain adjuvant, or not containing adjuvant) or hard capsule or soft capsule, if require also can cover by usual way peplos, inner component can sustained release.In this active component of such solid dosage forms, need and at least one inert diluent mixing, such as but not limited to lactose, sugarcane sugar and starch.Such dosage form also may contain except inert diluent other material, the lubricant of tablet for example, and sheet agent aid is magnesium stearate for example, rice flour and crystallite celluloid.Capsule, tablet or granular dosage form, also may contain buffer agent.The release of active component can be also only at certain part delayed release of intestinal.Those components can be sneaked in polymer or cured preparation.
Similar same dosage form solid constituent also can be used lactose and high molecular polymerization ethylene glycol as soft, the filler of hard capsule.
Liquid component also can with known method and by pharmaceutically or the liquid preparation of being accepted on health product and health medicine prepare.
If needed, component of the present invention can be incorporated to slow release or targeting delivery system.Polymeric matrix for example,
Liposome, and microsphere particle.These can be sterilized by bacteriological filtration filter, or by the disinfectant that is dissolved in sterilized water, or put into before use the injectable media of sterilization.
This invention component can be made granule, can add or not add adjuvant, and patient can directly take or component is added in applicable liquid, and patient drinks the liquid that contains component.This granule can contain effervescent tablet composition, can help like this component to be effectively dispersed in liquid medium.
The mode of taking of this invention composition can be being combined with above-mentioned one or more preparations of preparation.
Do not leaving in basic purpose of the present invention and category situation, embodiment and pharmaceutical formulation and instructions of taking can improve on more known technical methods and basis.
The mode that this component is released in body is numerous, as oral, and eye drop, system is released into (example is transdermal formula, nasal cavity, or suppository), parenteral (as intramuscular, intravenous injection or subcutaneous).In some case, the method for being released into is oral, takes number of times every day and can determine according to different factors such as state of an illness weights.Oral prescription can be tablet, granule, capsule, semisolid, powder, slow release prescription, liquid, suspension, spraying or other suitable methods.Also has in addition inhalation.
The selection of Recipe and component, is released into the mode in body, bioavailability, and treatment target is all correlated with.Oral is the modal mode of taking.In prescription that can be oral, common are solid as tablet, capsule, granule etc.But under special circumstances, oral soft capsule or liquid phase are to being more suitable for.
Component of the present invention can contain the adjuvant that solid drugs is used, starch for example, celluloid, Pulvis Talci, glucose, sucrose, lactose, gelatin, Fructus Hordei Germinatus, rice flour, flour, whiting, silica gel, magnesium stearate, glycerol monostearate, sodium stearate, sodium chloride, drying defatted milk, and similar substance etc.Liquid or semi-solid adjuvant can from but be not limited only to select following material glycerol, water, propylene glycol, ethanol, and all kinds of oil, comprise oil, animal oil, vegetable oil, or synthetic oil, Oleum Arachidis hypogaeae semen, Oleum Glycines, Oleum sesami or mineral oil, emulsifying agent, concentrating agents, wax etc.Liquid-carrier, particularly prepares injecting fluid, comprises water, saline, G/W and glycerol etc.
The consumption of this component or effective dose can prototype version determine, can be according to personal considerations, also can be according to its effect, and toxicology data and this component are to use separately or combine with other medicines or Therapeutic Method to use and change.As for animal, its method can further be determined the effect of this component.
Absorption method mediating recipe amount depends on therapeutic purposes, the target cell being treated and the object being treated.Can take in by one or many.Concrete scheme need to be selected as the case may be.
Said composition forms can be by oral, eye drop, non-intestinal or anapnotherapy.Can be tablet, buccal tablet, granule, capsule, pill, ampoule, suppository and aerosol.Also can be suspension, solution, emulsion, syrup, granule or powder face moisture or nonaqueous solvent type.Also can contain other medicine activity component, or various ingredients.
More particularly, this patent component can be active component, can be conducted in body with matched therapeutic modality, and as oral, nasal-cavity administration, external application (comprising transdermal patch, aerosol, oral cavity, Sublingual), parenteral conduction (comprise subcutaneous, intramuscular, intravenous, in skin etc.) and pulmonary administration.The absorption mode of this component and dosage can change according to age and the state of an illness.
This component need to manufacture this component for preparing medicament transdermal patch method patch or the sucker that can adhere, and medicine slow release absorbs and enters in body through skin.From this angle, penetration enhancer can be used for increasing the absorption of medicine.Being manufactured in following patent of transdermal patch has a detailed description
.U.S.?Patent?No.?5,407,713.;?U.S.?Patent?No.?5,352,456;?U.S.?Patent?No.?5,332,213;?U.S.?Patent?No.?5,336,168;?U.S.?Patent?No.?5,290,561;?U.S.?Patent?No.?5,254,346;?U.S.?Patent?No.?5,164,189;?U.S.?Patent?No.?5,163,899;?U.S.?Patent?No.?5,088,977;?U.S.?Patent?No.?5,087,240;?U.S.?Patent?No.?5,008,110;?and?U.S.?Patent?No.?4,921,475.
Component of the present invention also can be used for preparing the medicament for the treatment of optical fundus macular edema, prepares method and the technology of the medicine of this component and knows.
Above-mentioned component, comprises many special case study on implementation, can prepare production process with the medicine of standard and prepare, and the medication known to can Yong Bei the world of medicine is treated disease as described herein.
Example is below used for illustrating this patent, but the present invention is not limited to these examples.
The woman of 67 years old, because left eye central retina vein stops up, started to have optical fundus macular edema in 2005, two all found that there is little glass-film wart at that time.Her blood item checks: low density cholesterol, and blood glucose and blood triglyceride be higher than normal value,
After optical fundus expert doctor checks, immediately at her left eye injection cortisone, optical fundus macular edema has disappeared, but intraocular pressure is elevated to 35-40mmHg, doctor prescribed prescription collyrium control intraocular pressure.Nearly six months, her left eye started there is cataract, developed into very soon left eye and cannot see thing, under doctor advised, had done cataract operation.After operation, find that optical fundus macular edema has developed into the very order of severity.An optical fundus expert advice intravitreal injection Arastin (Avastin), this disappeared macular edema in one month, after 2-3 month, macular edema is got back to again serious situation, must again inject (as shown in Figure 1), this photo is photographed in June, 2008, when at intravitreal injection Arastin, after 3 months, optical fundus macular edema recurs again, take, macular edema is high-visible in this picture.Vision is at that time 20/40.Intraocular pressure is 35 mmHg.Immediately at intravitreal injection Arastin, keep normal within one month, arrive 3 months, edema recurrence, edema recurrence in after this every 3 months, needs again to repeat to accept intravitreal injection treatment.This patient accepts intravitreal injection treatment front and back as long as five years.Be presented at the appearance again of injection Arastin optical fundus macular edema after three months.The doctor told she, Arastin can maintain, but can not cure macular edema, this injection will be followed her remaining years.Every three months needs injection, and such situation is diagnosed as for the first time after the macular edema of optical fundus at the beginning of 2005, has continued nearly five years.
In October, 2009, latter two month starts to take component of the present invention this patient injection, once a day, after four months to the time of this injection goes to see the doctor again.
Ophthalmologist finds that her vision is greatly improved.The not recurrence of current optical fundus macular edema.Therefore this is through four months, not need again to inject after she injects Arastin over nearly 5 years for the first time.In January, 2011, reexamines, and has not injected more than a year Arastin, does not find optical fundus macular edema, vision 20/20, intraocular pressure 10mmHg.And vision is 20/40 in the time of 2005.So far triennium is not injected, and still keeps normal, and (as shown in Figure 2, OCT photo is in January, 2011), patient goes to see ophthalmologist routinely, arrives again the time of intravitreal injection, but is specifically after taking formula of the present invention.From OCT photo, optical fundus macular edema disappears, and does not therefore need the injection of Arastin.Vision 20/20, intraocular pressure 9 mmHg.So far, take recipe ingredient of the present invention every day.Within 3 years, do not need to inject again, and macular edema does not occur again.
89 years old patients women, are diagnosed as type ii diabetes in the time of 70 years old at her, she keeps on a diet under guidance and reduces taking the photograph of sugar, and within 2009, her vision obviously declines, thereby goes to see optical fundus expert doctor, finds the macular edema that two eyes have diabetes to cause.She sees that all linear type article are all wavy, and her blood pressure is normal, low density cholesterol and triglyceride normal, within 2010, she starts to take component of the present invention, take every day, adheres to 3 months, and her discovery sees that the phenomenon of the Wave curved of thing has not had.Her optical fundus macular edema obviously improves, and vision is also recovered to some extent.
78 years old male patient was once diagnosed as moist optical fundus macula lutea degeneration in 2005, also found at that time optical fundus macular edema out.This patient has accepted the treatment of pupil thermotherapy (TTT) and has processed, and 2010 start to take component of the present invention once a day, adhere to four months, then go to see the doctor, and his eye eyesight improves, and optical fundus macular edema obviously reduces.
79 years old women, left eye is accepted cataract operation at the beginning of suffering from cataract 2011, and postoperative discovery left eye has optical fundus macular edema, vision only have 20/60. she start to take component of the present invention, once a day, after three months, check, macular edema disappears, and vision is 20/20.
Claims (11)
1. the compositions that is used for the treatment of optical fundus macular edema, said composition comprises by weight percentage: (a) polyphenol compound of 0.4% ~ 71%, 0.6% ~ 93% (b) thioctic acid, dihydrolipoic acid, lipoate or lipoic acid polyacrylamide, 0% ~ 97% (c) ubiquinone or pantothenylol, 0% ~ 87% (d) docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
2. the compositions that is used for the treatment of optical fundus macular edema according to claim 1, it is characterized in that: said composition comprises by weight percentage: (a) polyphenol compound of 0.4% ~ 71%, 0.6% ~ 93% (b) thioctic acid, dihydrolipoic acid, lipoate or lipoic acid polyacrylamide, 0.6% ~ 97% (c) ubiquinone or pantothenylol, 0.15% ~ 87% (d) docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
3. the compositions that is used for the treatment of optical fundus macular edema according to claim 1, it is characterized in that: said composition comprises: (a) polyphenol compound of 25 ~ 800 milligrams, (b) thioctic acid, dihydrolipoic acid, lipoate or the lipoic acid polyacrylamide of 25 ~ 1800 milligrams, (c) ubiquinone or the pantothenylol of 0 ~ 1000 milligram, d) docosahexenoic acid of 0 ~ 2000 milligram or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
4. according to the compositions that is used for the treatment of optical fundus macular edema described in claim 1,2 or 3, it is characterized in that: said composition also comprises the vitamin A of 0 ~ 1000 IU, the vitamin B of 0 ~ 1000 milligram, vitamin C, the vitamin D of 0 ~ 5000 IU and the vitamin E of 0 ~ 800 IU of 0 ~ 2000 milligram, the zinc of 0 ~ 40 milligram, the magnesium of 0 ~ 900 milligram, the carotenoid material of 0 ~ 500 milligram.
5. the compositions that is used for the treatment of optical fundus macular edema as described in claim 1,2 or 3, is characterized in that: the former Hua Qingsu that described (a) polyphenol compound is oligomerization.
6. the compositions that is used for the treatment of optical fundus macular edema as described in claim 1,2 or 3 is for improving patient's vision stability intraocular pressure and reducing all kinds of inflammation of eye.
7. the compositions that is used for the treatment of optical fundus macular edema as described in claim 1,2 or 3 is used for the treatment of optical fundus macular edema.
8. the compositions that is used for the treatment of optical fundus macular edema as described in claim 1,2 or 3 is used for the treatment of patient has due to diabetes, hypertension, angiopathy comprises arteriosclerosis, cancer, all kinds of ophthalmics, optical fundus blood vessel disease, some rare disease, the optical fundus macular edema that smoking or ocular surgical cause and other ocular disease, described optical fundus blood vessel disease comprises that central retina vein stops up, branch retinal vein stops up, old optical fundus macula lutea degeneration, the combination of glaucoma or several diseases.
The compositions that is used for the treatment of optical fundus macular edema as described in claim 1,2 or 3 to take in the approach in body be oral, eye drip, intravitreal injection, intravenous drip, external preparation for skin, without intestinal, intraperitoneal, Sublingual or implant.
10. the daily dose that the compositions that is used for the treatment of optical fundus macular edema as described in claim 1,2 or 3 is taken in body is: the former Hua Qingsu of 30 ~ 300mg, 30 ~ 600mg thioctic acid, 50 ~ 300mg ubiquinone, 100 ~ 1500 milligrams of docosahexenoic acid or its ethyl ester, and/or eicosapentaenoic acid or its ethyl ester.
11. compositionss that are used for the treatment of optical fundus macular edema as described in claim 1,2 or 3 further add the anti-inflammation formulation of medical effective dose to patient, antibiotic medicine is oral formulations, eye drop, unguentum or transdermal patch, or further to patient, add by endothelial cell growth factor (ECGF) antibody class compositions, or further comprise laser coagulation therapeutic scheme.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210274126.9A CN103565801B (en) | 2012-08-02 | 2012-08-02 | For treating compositions and the said composition application in treatment ocular disease of eyeground macular edema |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210274126.9A CN103565801B (en) | 2012-08-02 | 2012-08-02 | For treating compositions and the said composition application in treatment ocular disease of eyeground macular edema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103565801A true CN103565801A (en) | 2014-02-12 |
| CN103565801B CN103565801B (en) | 2016-08-31 |
Family
ID=50039083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210274126.9A Active CN103565801B (en) | 2012-08-02 | 2012-08-02 | For treating compositions and the said composition application in treatment ocular disease of eyeground macular edema |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103565801B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105079009A (en) * | 2015-08-25 | 2015-11-25 | 厦门金达威集团股份有限公司 | Composition for preventing and /or treating cardiovascular and cerebrovascular diseases |
| CN113347950A (en) * | 2019-01-19 | 2021-09-03 | 红婴生物科技股份有限公司 | Ophthalmic lenses, pharmaceutical compositions and uses thereof |
| CN114053407A (en) * | 2020-09-17 | 2022-02-18 | 温州医科大学 | Application of regulating eye sclera lipid metabolism to inhibit myopia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031744A1 (en) * | 1997-02-04 | 2001-10-18 | Kosbab John V. | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
-
2012
- 2012-08-02 CN CN201210274126.9A patent/CN103565801B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031744A1 (en) * | 1997-02-04 | 2001-10-18 | Kosbab John V. | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105079009A (en) * | 2015-08-25 | 2015-11-25 | 厦门金达威集团股份有限公司 | Composition for preventing and /or treating cardiovascular and cerebrovascular diseases |
| CN105079009B (en) * | 2015-08-25 | 2018-05-01 | 厦门金达威生物科技有限公司 | Prevention and/or the composition for the treatment of cardiovascular and cerebrovascular disease |
| US10857108B2 (en) | 2015-08-25 | 2020-12-08 | Xiamen Kingdomway Group Company | Composition for preventing and/or treating cardiovascular and cerebrovascular diseases |
| CN113347950A (en) * | 2019-01-19 | 2021-09-03 | 红婴生物科技股份有限公司 | Ophthalmic lenses, pharmaceutical compositions and uses thereof |
| CN114053407A (en) * | 2020-09-17 | 2022-02-18 | 温州医科大学 | Application of regulating eye sclera lipid metabolism to inhibit myopia |
| WO2022057778A1 (en) * | 2020-09-17 | 2022-03-24 | 温州医科大学 | Application of regulation of eye sclera lipid metabolism to inhibit myopia |
| CN114053407B (en) * | 2020-09-17 | 2023-08-29 | 极目峰睿(上海)生物科技有限公司 | Application of regulating scleral lipid metabolism of eye to inhibit myopia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103565801B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6627620B1 (en) | Composition set and kit for use in intraocular surgery | |
| US20110052678A1 (en) | Method for treating age related macular degeneration | |
| AU2017329772A1 (en) | Pharmaceutical compositions for use in the therapy of blepharitis | |
| CN103338758A (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| ZA200510344B (en) | Coumarin derivatives for the treatment of ophthalmic disorders | |
| CN112955125B (en) | Topical injectable compositions | |
| RU2005106234A (en) | APPLICATION OF ANECORTA ACETATE FOR THE PROTECTION OF VITAL EYE-ACUTE OF PATIENTS WITH AGE YELLOW SPOT DEGENERATION | |
| CN103565801B (en) | For treating compositions and the said composition application in treatment ocular disease of eyeground macular edema | |
| CN102166203A (en) | Eye pad for alleviating eye fatigue and preparation method thereof | |
| CN110075148A (en) | Arasaponin extract is preparing the application in eye medicinal preparation | |
| TW201815397A (en) | Ophthalmic agent and ophthalmologic drug | |
| Pathanapitoon et al. | Choroidal detachment after topical prostaglandin analogs: case report | |
| RU2314069C1 (en) | Method for preparing patients before operation to surgical treatment of cataract complicated with glaucoma | |
| Yeom et al. | Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd: YAG laser posterior capsulotomy | |
| CN108210683A (en) | A kind of pharmaceutical composition for treating glaucoma | |
| US20230210801A9 (en) | Compositions for improving eye health and methods of making and using thereof | |
| Augustin et al. | Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases | |
| EP4364722A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor | |
| KR102275250B1 (en) | Composition for preventing and treating dry eye syndrome comprising selenium and propolis as active ingredients | |
| CN100508987C (en) | Application of hyaluronate in preparing oral products used for preventing or improving ocular vitreous degeneration disease | |
| CN113271934B (en) | Composition for treating or preventing diabetic cataract | |
| Rojanapongpun et al. | Medical Therapy in Angle Closure Glaucoma | |
| CN105983005A (en) | Composition capable of alleviating asthenopia and preparation method of composition | |
| Xie et al. | O antagonista das prostaglandinas alivia a ruptura da barreira sanguínea retiniana induzida pela cirurgia intraocular do segmento anterior em um modelo em ratos | |
| Onal et al. | Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |